Ablation Versus Sublobar Resection and Stereotactic Body Radiation Therapy for Early Stage Non–Small Cell Lung Cancer: an Analysis of 64,505 Patients from the National Cancer Database
C. Su,J. Wu,H. X. Bai,P. J. Zhang,G. Karakousis,S. J. Hunt,Z. Zhang
DOI: https://doi.org/10.1016/j.ijrobp.2018.07.1903
2018-01-01
Abstract:Lung resection has been the gold standard treatment for patients with early stage non–small cell lung cancer (NSCLC). For non-surgical candidates, stereotactic body radiation therapy (SBRT) and ablation have demonstrated high rates of local control with low morbidity. The primary aim of this study is to compare ablation vs. resection and SBRT for treating NSCLC. Patients with early stage (T1-T2aN0M0) NSCLC diagnosed from 2004 to 2014 who were treated with ablation, sublobar resection or SBRT were identified from the National Cancer Database. Overall survival (OS) was evaluated by log-rank test, multivariable Cox proportional hazard regression, and propensity score-matched analysis based on factors significant on univarable Cox regression analysis for OS and logistic regression for receipt of ablation versus sublobar resection or SBRT. Relative survival analyses compared to age- and gender-matched US population were performed. Among the 64,505 patients included in the study, 40,748 received sublobar resection, 22,967 received SBRT, and 790 received ablation. Patients with Charlson-Deyo score ≥ 2 were more likely to received ablation (19.1%) than sublobar resection (15.6%) or SBRT (16.3%). Ablation was associated with shorter OS when compared with sublobar resection (HR, 2.116; P< 0.001) or SBRT (HR, 1.248; P< 0.001) on multivariate analysis. Propensity score matching (1:2 ratio) based on age, gender, race, year, Charlson-Deyo score, primary site, tumor size, time duration, histology, grade, and stage resulted in 721 patients in the ablation group versus 1353 in the sublobar resection group, and 725 patients in the ablation group and 1446 in the SBRT group. After matching, shorter OS persisted in the ablation group compared to sublobar resection (median, 33.4 vs 62.4 months; HR, 2.162; p< 0.001) or SBRT (median, 33.3 vs 40.4 months; HR, 1.275; p< 0.001). Relative to an age- and gender-matched US population, the five-year survival rates were 35% (95% CI, 30-41%), 49% (95% CI, 45054%), and 72% (95% CI, 67-76%) for the ablation, SBRT, and sublobar resection group, respectively. For patients with early stage NSCLC, ablation appears to be associated with shorter OS compared to sublobar resection or SBRT.